Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | CA9 | Q16790 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9401432 | 0.86 | CA1 (0.55) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL4203567 | 0.86 | CA1 (0.55) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL10099484 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL15326594 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL14605408 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL14853701 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL16661388 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL13222912 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL15588618 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 | |
| SCHEMBL14817675 | 0.84 | CA1 (0.57) | CA1CA2CA9LMNACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SANKYO COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
| EP-1702926-A1 | LEVULOSE GLUCOSELIPID A ANALOGUE | Sankyo Company, Limited (JP) | 2006-09-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062214-A1 | Left-Side Glucose Lipid a Analogue | SLC2A3, GPR119, SLC2A2 | CA1 2043/4885CA2 502/4885CA9 1485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.